RemeGen Co., Ltd.

SZSC:9995 Stock Report

Market Cap: HK$16.1b

RemeGen Valuation

Is 9995 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 9995 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 9995 (HK$16.74) is trading below our estimate of fair value (HK$73.42)

Significantly Below Fair Value: 9995 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 9995?

Key metric: As 9995 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 9995. This is calculated by dividing 9995's market cap by their current revenue.
What is 9995's PS Ratio?
PS Ratio5.5x
SalesCN¥1.52b
Market CapCN¥14.98b

Price to Sales Ratio vs Peers

How does 9995's PS Ratio compare to its peers?

The above table shows the PS ratio for 9995 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.3x
1530 3SBio
1.4x9.3%HK$13.0b
6826 Shanghai Haohai Biological Technology
2.1x11.8%HK$13.9b
9969 InnoCare Pharma
11.2x25.9%HK$12.9b
6660 AIM Vaccine
6.2xn/aHK$7.9b
9995 RemeGen
5.5x25.9%HK$16.1b

Price-To-Sales vs Peers: 9995 is expensive based on its Price-To-Sales Ratio (5.5x) compared to the peer average (5.3x).

Price to Sales Ratio vs Industry

How does 9995's PS Ratio compare vs other companies in the HK Biotechs Industry?

14 CompaniesPrice / SalesEstimated GrowthMarket Cap
6826 Shanghai Haohai Biological Technology
2.1x11.8%US$1.79b
1530 3SBio
1.4x9.3%US$1.67b
2696 Shanghai Henlius Biotech
1.8x10.1%US$1.41b
775 CK Life Sciences Int'l. (Holdings)
0.8xn/aUS$549.41m
9995 5.5xIndustry Avg. 11.9xNo. of Companies14PS01632486480+
14 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 9995 is good value based on its Price-To-Sales Ratio (5.5x) compared to the Hong Kong Biotechs industry average (11.9x).

Price to Sales Ratio vs Fair Ratio

What is 9995's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

9995 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.5x
Fair PS Ratio7.2x

Price-To-Sales vs Fair Ratio: 9995 is good value based on its Price-To-Sales Ratio (5.5x) compared to the estimated Fair Price-To-Sales Ratio (7.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 9995 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentHK$16.74
HK$25.03
+49.5%
31.9%HK$48.84HK$16.00n/a16
Nov ’25HK$19.30
HK$25.63
+32.8%
32.6%HK$49.61HK$16.02n/a15
Oct ’25HK$17.10
HK$25.20
+47.3%
36.7%HK$50.29HK$15.39n/a14
Sep ’25HK$12.46
HK$24.98
+100.5%
36.6%HK$49.73HK$15.22n/a14
Aug ’25HK$14.30
HK$37.85
+164.7%
30.1%HK$63.00HK$21.00n/a14
Jul ’25HK$24.50
HK$39.94
+63.0%
25.2%HK$63.00HK$27.92n/a13
Jun ’25HK$25.35
HK$41.86
+65.1%
26.9%HK$62.96HK$27.93n/a14
May ’25HK$27.95
HK$42.88
+53.4%
25.8%HK$62.99HK$27.94n/a13
Apr ’25HK$27.15
HK$44.74
+64.8%
29.1%HK$62.99HK$25.88n/a12
Mar ’25HK$22.35
HK$53.28
+138.4%
24.9%HK$66.42HK$26.01n/a13
Feb ’25HK$17.04
HK$55.48
+225.6%
19.5%HK$66.76HK$27.16n/a13
Jan ’25HK$37.45
HK$57.51
+53.6%
13.0%HK$66.99HK$38.46n/a13
Dec ’24HK$45.15
HK$57.51
+27.4%
13.0%HK$66.99HK$38.46n/a13
Nov ’24HK$44.55
HK$55.79
+25.2%
12.8%HK$65.27HK$37.48HK$19.3014
Oct ’24HK$40.30
HK$56.31
+39.7%
15.8%HK$68.03HK$36.20HK$17.1015
Sep ’24HK$36.60
HK$58.51
+59.9%
9.3%HK$67.04HK$48.49HK$12.4614
Aug ’24HK$45.30
HK$61.22
+35.1%
9.7%HK$68.72HK$48.92HK$14.3013
Jul ’24HK$34.25
HK$62.01
+81.1%
11.3%HK$74.88HK$48.77HK$24.5013
Jun ’24HK$32.10
HK$63.41
+97.5%
11.3%HK$76.71HK$49.97HK$25.3513
May ’24HK$45.80
HK$64.87
+41.6%
11.9%HK$79.84HK$50.00HK$27.9513
Apr ’24HK$41.85
HK$68.25
+63.1%
7.4%HK$80.35HK$60.51HK$27.1512
Mar ’24HK$54.45
HK$73.97
+35.8%
8.7%HK$86.53HK$64.00HK$22.3512
Feb ’24HK$66.45
HK$72.79
+9.5%
9.3%HK$87.90HK$64.74HK$17.0412
Jan ’24HK$57.90
HK$70.36
+21.5%
9.5%HK$83.96HK$61.84HK$37.4513
Dec ’23HK$47.95
HK$70.90
+47.9%
9.5%HK$84.08HK$61.92HK$45.1512
Nov ’23HK$49.40
HK$67.10
+35.8%
9.8%HK$77.79HK$53.00HK$44.5511

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

3SBio

HK$13.0b

An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.

1530

HK$5.52

7D

-4.3%

1Y

-26.2%

China Shineway Pharmaceutical Group

HK$6.1b

An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.

2877

HK$8.13

7D

-3.3%

1Y

n/a

Innovent Biologics

HK$60.6b

A biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China.

1801

HK$37.00

7D

-0.5%

1Y

-15.4%